Past Speakers include: / 3rd Annual Meeting World ADC by Hanson Wade

Dr Gail Phillips Scientist, Research Oncology Genentech Gail received her graduate degree from University of Texas Southwestern Medical Center. Her laboratory focuses on targeting receptor tyrosine kinases with monoclonal antibodies for the development of anti-cancer therapeutics.

Paul Davis Chief Executive Officer Quanta BioDesign Paul’s vision for Quanta BioDesign is to fully develop a broad range of specifically designed single molecule reagents for therapeutic and diagnostic applications. He received his Ph.D. from Bowling Green State University.

Tom Davis Chief Medical Officer Celldex Therapeutics Dr. Davis has been involved in clinical cancer immunotherapy in academia, government and industry for over a decade. He trained at Johns Hopkins, Georgetown and Stanford Universities.

Jonathan Drachman Senior Vice President Seattle Genetics Jonathan oversees Seagen’s research, preclinical and early clinical development activities. He is also a Clinical Associate Professor of Medicine in the Hematology Division, Department of Medicine at the University of Washington in Seattle.

Pamela Trail Vice President Regeneron Pam’s career has spanned two decades. She has served as the VP of Oncology at MedImmune and held positions at Seattle Genetics, Bayer and BMS. She received her PhD from the University of Connecticut.

Eric Poma CEO Molecular Templates Eric has over 15 years of biotech company and drug development experience. He has served as CEO and CSO of Molecular Templates since its inception. He holds a PhD in Microbiology and Immunology from the University of North Carolina.

David Satijn Associate Director Genmab Dr. David Satijn holds a PhD in Molecular Biology from the University of Amsterdam. In 2006, he joined Genmab and is currently supervising target discovery and novel antibody programs.

Kathleen Elias Director Takeda San Francisco Dr. Elias' principal responsibilities include managing the research and development activities in the pharmacology, pathology and translational medicine groups. Prior to joining Takeda San Francisco, Dr. Elias served as Principal Scientist at Cytokinetics.

Dr. Jonathan Terrett Chief Scientific Officer Oxford BioTherapeutics Ltd Jon has been a pioneer in the use of proteomics to feed the development of targeted therapeutic antibodies for the treatment of cancer since 1999 with a focus on ADC targets since the technology began to mature in the early 2000’s. Read more...

Hans Erickson Principal Scientist ImmunoGen Hans Erickson received his Ph.D. in Biochemistry from the University of California, San Diego. At ImmunoGen, his efforts are focused on understanding the mechanisms associated with efficacy and toxicity of antibody-drug conjugates.

Dr Vincent de Groot Chief Executive Officer Syntarga Dr. de Groot obtained his Ph.D. degree from the Radboud University Nijmegen. He is a member of the AACR, ACS and LES. He holds a Certified Licensing Professional credential from LES.

Dr Tom Davis Senior Vice President, Chief Medical Officer Celldex Therapeutics Dr. Davis has been involved in clinical cancer immunotherapy in academia, government and industry for over a decade. He trained at Johns Hopkins, Georgetown and Stanford Universities.

Joseph J. Kenny, Ph.D., J.D. Chief Patent Counsel ImmunoGen, Inc Dr. Kenny has over 15 years of experience in biotechnology and has been Chief Patent Counsel at ImmunoGen, Inc. since 2009. Read more...

Manish Gupta Scientist Genentech Prior to joining Genentech, Manish was a Manager of Clinical Pharmacology at Pfizer. He received his PhD from the University of Tennessee.

Anna Wu Professor UCLA Dr. Wu’s research focuses on engineering antibodies to optimize their clinical utility; her laboratory developed engineered fragments such as minibodies and cys-diabodies for rapid targeting and imaging using PET.

Jagath Junutula Senior Scientist Genentech Jagath is a Group Leader in the Research and Early Development Division. He obtained his Ph.D. from Indian Institute of Science. He did post-doctoral research in Germany and at Stanford University.

Adeela Kamal Associate Director MedImmune Dr. Adeela Kamal has over 10 years of experience in oncology drug discovery for both small molecules and biologics. She leads MedImmune’s ADC efforts as well as managing other preclinical oncology programs.

Frank Kogelberg Manager, Contract Manufacturing Baxter Frank Kogelberg has been a manager contract manufacturing at Baxter in since 2007. He is responsible for program management and process transfers of client products to the Baxter facility in Halle/Westfalen.

John Lambert Executive Vice President & Chief Scientific Officer ImmunoGen John M. Lambert, Ph.D joined ImmunoGen in 1987. Prior to this, Dr. Lambert was an Assistant Professor at Harvard Medical School. Dr. Lambert holds a Ph.D. in Biochemistry from University of Cambridge.

Paul Polakis Director, Cancer Targets Genentech Paul worked at Genentech as a postdoc and returned as a Senior Scientist. He leads the Tumor Antigen Project in an effort to identify tumor cell markers to serve as targets for therapeutic antibodies.

Hans Peter Gerber Senior Director, Bioconjugates and Vascular Biology Pfizer

Neil Bander Professor Weill Cornell Medical College In addition to his professorship, Neil is a Fellow at the Memorial Sloan-Kettering cancer centre, where he’s been a member for 28 years. He received his medical degree from John Hopkins University.

Michael Bienkowski Manager, Process Development SAFC Michael joined SAFC last year. He was previously a research fellow at Pfizer, and held positions at Pharmacia and Upjohn. He received his PhD in Biochemistry from the University of Illinois.

Ulrich Brinkmann Scientific Director Roche Dr Brinkmann leads a Protein Engineering unit within Roche Pharma Research in Penzberg, Germany. Prior to that, he served as CSO at Xantos and Epidauros.

Ho Cho Chief Technology Officer Ambrx Dr. Ho Sung Cho has over 20 years of experience in recombinant protein expression, purification, modification, and analysis. He received his PhD from the University of California at Berkeley.

Shane Olwill Senior Director Pieris Before joining Pieris earlier this year, Shane was a Director of Research and Development at Fusion Antibodies Ltd. He received his PhD from the University of Ulster in 2003.

Leonard Reyno Chief Medical Officer Agensys Dr Reyno joined Agensys in 2007. Prior to this, he served as the Senior Director at Cytokines, and a Medical Director at Genentech. He is also a Physician.

Tom Rohrer Senior Director Lonza Thomas has 28 years of experience in protein expression and purification. He joined Lonza through the Cambrex acquisition where he led scale-up and manufacturing of ADCs.

Samadhi Vitharana Senior Scientist Takeda San Francisco Prior to joining Takeda, Samadhi held positions at BioMarin and Genitope. She received her PhD from the University of Kansas.

Aditya Wakankar Scientist Genentech Aditya received his PhD from the University of Kansas. He specialises in chemical stability of peptides and proteins, biophysical characterization of ADCs; and their formulation development.

Mike Wheatcroft Research Manager Avipep Mike has previously held positions at Victorian Cancer Biologics, MedImmune and the University of Cambridge. His specialities include protein production & characterization with a particular emphasis in antibody engineering and formation of ADCs.